Morgan Stanley Rain Therapeutics Inc. Transaction History

Morgan Stanley

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.84 - $1.22 $39,082 - $56,762	46,527 New	46,527 $55,000
Q4 2023 Feb 13, 2024	BUY	$0.84 - $1.22 $23,892 - $34,700	28,443 Added 157.28%	46,527 $55,000
Q3 2023 Nov 15, 2023	SELL	$0.82 - $1.42 $32,103 - $55,594	-39,151 Reduced 68.4%	18,084 $15,000
Q2 2023 Aug 14, 2023	BUY	$1.09 - $9.93 $35,877 - $326,845	32,915 Added 135.34%	57,235 $68,000
Q1 2023 May 15, 2023	BUY	$7.77 - $12.47 $93,496 - $150,051	12,033 Added 97.93%	24,320 $212,000
Q4 2022 Feb 14, 2023	BUY	$5.52 - $8.48 $7,175 - $11,024	1,300 Added 11.83%	12,287 $98,000
Q3 2022 Nov 14, 2022	SELL	$4.75 - $8.01 $36,494 - $61,540	-7,683 Reduced 41.15%	10,987 $53,000
Q2 2022 Oct 27, 2022	BUY	$2.21 - $5.56 $21,996 - $55,338	9,953 Added 114.18%	18,670 $105,000
Q2 2022 Aug 15, 2022	BUY	$2.21 - $5.56 $21,996 - $55,338	9,953 Added 114.18%	18,670 $105,000
Q1 2022 Oct 27, 2022	SELL	$5.07 - $13.68 $50,461 - $136,157	-9,953 Reduced 53.31%	8,717 $44,000
Q1 2022 May 13, 2022	BUY	$5.07 - $13.68 $19,347 - $52,202	3,816 Added 77.86%	8,717 $44,000
Q4 2021 Feb 14, 2022	BUY	$11.91 - $17.0 $40,958 - $58,463	3,439 Added 235.23%	4,901 $63,000
Q3 2021 Nov 15, 2021	BUY	$13.21 - $20.91 $19,313 - $30,570	1,462 New	1,462 $21,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.